TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
The review includes potential asset sales and partnerships, while TTX-MC138 continues in Phase 2a clinical development.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TransCode Therapeutics (Nasdaq: RNAZ) has initiated a formal strategic process to evaluate opportunities for the company and its oncology portfolio. It retained Tungsten Advisors as exclusive strategic financial advisor. Alternatives include asset licensing or sales, development and commercialization partnerships, portfolio transactions and business combinations.
Lead candidate TTX-MC138 is in Phase 2a development for colorectal cancer patients with circulating tumor DNA after curative-intent treatment. Its Phase 1a study met the primary safety endpoint, with no dose-limiting toxicities reported across evaluated doses. In the September 2026 update, 10 of 14 efficacy-evaluable patients had stable disease as their best response by investigator assessment; these preliminary findings require confirmation in larger studies.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointPhase 1a met its primary safety endpoint, with no dose-limiting toxicities across evaluated dose levels.
- Moderate point. Forward-looking: it has not happened yet and may not happen.The strategic process will evaluate asset licensing, sales, partnerships, portfolio transactions and business combinations.
- Moderate pointTTX-MC138 advanced into Phase 2a development for ctDNA-positive colorectal cancer following curative-intent treatment.
- Minor point10 of 14 efficacy-evaluable patients achieved investigator-assessed stable disease as best response in the September 2026 update.
- Minor point. Forward-looking: it has not happened yet and may not happen.Natera collaboration aims to identify eligible Phase 2a patients and support more efficient enrollment.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Preliminary Phase 1a findings require confirmation in larger studies.
News Explained
The process has no assured transaction outcome: the company says it may produce no transaction or other strategic result, and it does not expect to update unless the board approves a specific transaction or course of action, or disclosure is otherwise appropriate or required.
Details
Market Reaction – RNAZ
On Oct 28, the day this news came out, the latest delayed price for RNAZ is 0.57% above the previous close. Our momentum scanner has recorded 6 alerts for this stock so far that day. The latest delayed price is $1.75.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Stable disease
- 10 of 14 patients
- September 2026 update; best overall response by investigator assessment
- Planned trial enrollment
- Up to 45 patients
- Phase 2a colorectal cancer trial
Historical Context
-
TTX-MC138 data reported no dose-limiting toxicities and disease stabilization.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ctdna medical
dose-limiting toxicities medical
molecular residual disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Lead program TTX-MC138 is in Phase 2a clinical development for ctDNA-positive colorectal cancer following curative-intent treatment
TransCode will evaluate strategic alternatives including licensing arrangements, development partnerships and other strategic transactions
The process will evaluate a broad range of potential transactions involving the Company, its lead therapeutic candidate TTX-MC138 and its other oncology programs. Potential opportunities may include a licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations or other strategic transactions.
TransCode has engaged Tungsten Advisors as the Company's exclusive strategic financial advisor in connection with the process.
"TTX-MC138 has advanced into Phase 2a clinical development following our Phase 1a study, which provided initial safety data and reports of stable disease," said Philippe P. Calais, PharmD, PhD., CEO and Chairman. "We believe a formal strategic process will help us evaluate opportunities to support the continued development of TTX-MC138 and our broader oncology portfolio, while seeking to maximize value for our stockholders."
TTX-MC138 is an investigational RNA-based therapeutic designed to inhibit microRNA-10b (miR-10b), which is implicated in metastatic cancer cell survival and disease progression. The program is being evaluated in a Phase 2a trial in patients with circulating tumor DNA (ctDNA)-positive colorectal cancer following curative-intent therapy, in collaboration with Quantum Leap Healthcare Collaborative under its PRE-I-SPY program.
On October 13, 2026, TransCode and Natera, Inc. announced a collaboration to support enrollment in the Phase 2a trial. TransCode will use Natera's Signatera test to identify patients who have completed curative-intent therapy and test positive for molecular residual disease despite having no radiographic evidence of disease. The collaboration aims to improve identification of eligible patients at participating sites and support more efficient trial enrollment.
There can be no assurance that the strategic process will result in any transaction or other strategic outcome. TransCode does not intend to provide updates on the process unless and until its Board of Directors approves a specific transaction or course of action, or the Company otherwise determines that disclosure is appropriate or required.
About TransCode Therapeutics
TransCode Therapeutics is an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis, and is currently being evaluated in a Phase 2a trial under the PRE-I-SPY program in collaboration with Quantum Leap Healthcare Collaborative. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. For more information,visit www.transcodetherapeutics.com.
About TTX-MC138
TTX-MC138 is TransCode's lead therapeutic candidate and is designed to inhibit miR-10b. Its Phase 1a dose-escalation study in patients with advanced solid tumors met its primary safety endpoint, with no dose-limiting toxicities reported across the evaluated dose levels. In the Company's September 2026 update, 10 of 14 efficacy-evaluable patients achieved stable disease as their best overall response by investigator assessment. These preliminary findings require confirmation in larger studies.
The Phase 2a trial is designed to evaluate TTX-MC138 in up to 45 patients with colorectal cancer who have completed curative-intent treatment and have no radiographic evidence of disease but remain or become ctDNA-positive, indicating minimal residual disease. TTX-MC138 remains investigational and has not been approved for commercial use.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the Company's strategic process; its potential timing, structure, benefits and outcome; the possibility of any licensing transaction, asset sale, partnership, business combination or other strategic transaction; the development, regulatory approval and commercialization of TTX-MC138 and other product candidates; their potential therapeutic benefits and market opportunities; and the Natera collaboration, including the anticipated use of Signatera and its expected impact on patient identification and trial enrollment. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the possibility that the strategic process may not result in a transaction; the Company's ability to identify, negotiate and complete a transaction on acceptable terms; disruption to its business during the process; its need for additional capital and ability to obtain financing; risks associated with clinical trials, including whether early findings will be confirmed in later studies; regulatory review and approval; intellectual property protection; reliance on third parties; the Company's ability to maintain the listing of its common stock on Nasdaq, including compliance with the minimum bid price requirement; and competition. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode's actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled "Risk Factors" in TransCode's Annual Report on Form 10-K for the year ended December 31, 2025, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this release; TransCode undertakes no duty to update this information unless required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/transcode-therapeutics-retains-tungsten-advisors-to-lead-formal-strategic-process-intended-to-maximize-value-of-ttx-mc138-and-its-oncology-portfolio-302922687.html
SOURCE TransCode Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What strategic alternatives is TransCode Therapeutics evaluating?
TransCode is evaluating asset licensing or sales, development and commercialization partnerships, portfolio transactions, business combinations and other strategic transactions. The process covers the company, TTX-MC138 and its other oncology programs, with Tungsten Advisors serving as exclusive strategic financial advisor.
Who can enroll in TransCode's TTX-MC138 Phase 2a trial?
The trial is designed to evaluate up to 45 colorectal cancer patients who have completed curative-intent treatment, have no radiographic evidence of disease, and remain or become positive for circulating tumor DNA, indicating minimal residual disease. TransCode will use Natera's Signatera test to identify eligible patients.
When will TransCode provide updates on its strategic review?
TransCode does not intend to provide updates until its Board approves a specific transaction or course of action, unless the company otherwise determines disclosure is appropriate or required.